The Max Foundation Renews and Expands Agreement with Incyte
The Max Foundation is proud to announce it has signed a renewed collaboration agreement with Incyte – a dedicated pharmaceutical partner and member of our humanitarian pact.
Since February 2017, Incyte has partnered with The Max Foundation to assist patients with cancer in Central Asia and Eastern Europe who are in need and unable to access treatment. The renewal by Incyte will allow The Max Foundation, through our drug donation program Max Access Solutions, to expand the number of patients who may be eligible to receive treatment with Iclusig (ponatinib) from 35 to up to 50 at no cost for as long as needed.
“As we work to expand treatment access for patients in low-income countries, we are grateful to have committed partners like Incyte,” said Pat Garcia-Gonzalez, CEO and co-founder of The Max Foundation. “We’re so excited to not only continue our collaboration, but also to expand its size and bring effective medicine to more patients in need.”
“At Incyte we are fully aligned with the mission of The Max Foundation, focused on increasing patient access to care, support, and treatment,” added Jonathan Dickinson, General Manager of Incyte in Europe. “We are proud to be part of a program dedicated to making cancer treatments available to appropriate patients in Central Asia and Eastern Europe. We are happy and privileged to partner with and support to The Max Foundation’s efforts and look forward to another year of making a difference for patients with cancer.”
We at The Max Foundation express our thanks to Incyte for their continued collaboration, and will keep an ear out for the Incyte Bell (pictured below, and rung once each week for each new patient treated).
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
Related Articles
First Doses of CLL treatment provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
Armenia and Nepal are the first of 29 countries to receive CLL treatment SEATTLE & BASEL & BEIJING & CAMBRIDGE, Mass. – March 13, 2024 — The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene, a global oncology company, and….
The Max Foundation Announces Agreement with Lilly to Provide Access to Verzenio® (abemaciclib) for the Treatment of Advanced Breast Cancer in Kenya
Agreement to provide Verzenio® (abemaciclib) free of charge to patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) Lilly joins ongoing effort of Humanitarian Partnership for Access to Critical Treatment (Humanitarian PACT) to eliminate healthcare disparities for patients living with advanced breast cancer in low- and middle-income countries….
Tanner Pharma Group Delivers on “Last Mile” in Global Health
Tanner Pharma Group will serve as the title sponsor for The Max Foundation’s 2018 campaign “Max Global Experience: Uganda,” an expedition to raise awareness and funds for increased cancer treatment access in Africa.
The Max Foundation uses cookies to improve your experience on our site. Please read our Privacy Policy for more information.
